Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05577715 · ClinicalTrials.gov registry record · Phase 2
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT05577715 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants.
The verdict
NCT05577715, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Interventions
- DRUG MORAb-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05577715
The ClinicalTrials.gov registry entry for NCT05577715 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MORAb-202 is the first listed.
NCT05577715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05577715 about?
NCT05577715 is a clinical study titled "A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)". The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
What is the current status of trial NCT05577715?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2022-11-14. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT05577715?
The interventions under investigation include: MORAb-202 (DRUG).
Who is sponsoring clinical trial NCT05577715?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.